CNBX Pharmaceuticals (CNBX Pharmaceuticals) Cash-to-Debt : 0.03 (As of Feb. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CNBX Pharmaceuticals's cash to debt ratio for the quarter that ended in Feb. 2024 was 0.03.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, CNBX Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

The historical rank and industry rank for CNBX Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

CNBX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: No Debt Max: No Debt
Current: 0.03

During the past 13 years, CNBX Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was No Debt.

CNBX's Cash-to-Debt is ranked worse than
97.27% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs CNBX: 0.03

CNBX Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for CNBX Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CNBX Pharmaceuticals Cash-to-Debt Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.59

0.07

0.10

CNBX Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Cash-to-Debt	Get a 7-Day Free Trial															0.03	0.03	0.10	0.06	0.03

Competitive Comparison of CNBX Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, CNBX Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNBX Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Cash-to-Debt falls into.

CNBX Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

CNBX Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.13	/	(1.344	+	0)
	=	0.10

CNBX Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.037	/	(1.293	+	0)
	=	0.03

CNBX Pharmaceuticals (OTCPK:CNBX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

CNBX Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary